Elite Pharma Inc (ELTP) 0.3035 $ELTP The Price Data

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2015 at 2:01 PM

Elite Pharma Inc (ELTP) 0.3035 $ELTP

The Price Data Tells the Story - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Barrett Business Services and Ekso Bionics Holdings
ACCESSWIRE - Mon Nov 16, 7:02AM CST
NEW YORK, NY ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc (NASDAQ: NWBO),Elite Pharmaceuticals Inc (OTC: ELTP), Barrett Business Services Inc (NASDAQ: BBSI) and Ekso Bionics Holdings Inc (OTC: EKSO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.47 (+0.04), BBSI: 41.27 (+0.77)

Direction of Market Influences - Research on PositiveID, Elite Pharmaceuticals, Century Communities and Innerworkings
ACCESSWIRE - Thu Nov 12, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / November 12, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: PositiveID Corp (OTC: PSID), Elite Pharmaceuticals Inc (OTC: ELTP), Century Communities Inc (NYSE: CCS) and Innerworkings Inc (NASDAQ: INWK). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CCS: 18.46 (-0.33), INWK: 7.77 (-0.03)

Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
GlobeNewswire - Mon Nov 09, 3:37PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second quarter of its 2016 fiscal year.

Equities Lead Investor Sentiment - Research on Elite Pharmaceuticals, Medical Marijuana, Ekso Bionics Holdings and Pharmacyte Biotech
ACCESSWIRE - Mon Nov 09, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 9, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Elite Pharmaceuticals Inc (OTC: ELTP),Medical Marijuana Inc (PINKSHEETS: MJNA), Ekso Bionics Holdings Inc (OTC: EKSO) and Pharmacyte Biotech Inc (OTC: PMCB). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Penny Stocks Recap for Endeavor IP, Hemp, Elite Pharmaceuticals, Roadships, Eventure Interactive, and KollagenX
PR Newswire - Fri Nov 06, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Endeavor IP (OTCBB: ENIP), Hemp (OTCMKTS: HEMP), Elite Pharmaceuticals (OTCMKTS: ELTP), Roadships (OTCMKTS: TTCM), Eventure Interactive (OTCBB: EVTI), and KollagenX (OTCMKTS: KGNX).

Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 2nd Quarter 2016 Financial Results on November 10, 2015
GlobeNewswire - Thu Nov 05, 4:12PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCQB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its second quarter financial results will be released on Monday, November 9, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, November 10th at 11:00 a.m. EST to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks.

Equities Lead Investor Sentiment - Research on PositiveID, Elite Pharmaceuticals, Century Communities and iShares PHLX Semiconductor
ACCESSWIRE - Thu Nov 05, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 5, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: PositiveID Corp (OTC: PSID),Elite Pharmaceuticals Inc (OTC: ELTP), Century Communities Inc (NYSE: CCS) and iShares PHLX Semiconductor ETF (NASDAQ: SOXX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CCS: 18.46 (-0.33), SOXX: 88.91 (+0.74)

Penny Stocks Recap for EKSO BIONICS, Hemp, Agrieuro, GLOBAL DIGITAL SOLTN, Urban Barns Foods, and Elite Pharmaceuticals
PR Newswire - Wed Nov 04, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EKSO BIONICS (OTCBB:EKSO), Hemp (OTCMKTS:HEMP), Agrieuro (OTCBB:EURI), GLOBAL DIGITAL SOLTN (OTCMKTS:GDSI), Urban Barns Foods (OTCMKTS:URBF), and Elite Pharmaceuticals (OTCMKTS:ELTP).

Direction of Market Influences - Research on Pharmacyte Biotech, NuGene International, Rainbow Coral Corp and Elite Pharmaceuticals
ACCESSWIRE - Mon Nov 02, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Pharmacyte Biotech Inc (OTC: PMCB), NuGene International Inc (OTC: NUGN), Rainbow Coral Corp (OTC: RBCC) and Elite Pharmaceuticals Inc (OTC: ELTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.

The Reason It Trades, Quarterly Results, Project Financing and Strategic Acquisitions - Research on Dominovas Energy, Priority Aviation, Elite Pharmaceuticals, PositiveID
ACCESSWIRE - Thu Oct 29, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / October 29, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked about situations on wall street today: Dominovas Energy Corporation (OTC: DNRG), Priority Aviation, Inc. (OTC: PJET) Elite Pharmaceuticals Inc. (OTC: ELTP) and PositiveID Corporation (OTC: PSID).

Penny Stocks Alerts for Elite Pharmaceuticals, Guided Therapeutics, PositiveID, EKSO BIONICS, ANAVEX LIFE SCIENCES, and Dominovas Energy
PR Newswire - Wed Oct 28, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Elite Pharmaceuticals (OTCMKTS:ELTP), Guided Therapeutics (OTCBB:GTHP), PositiveID (OTCMKTS

SID), EKSO BIONICS (OTCBB:EKSO), ANAVEX LIFE SCIENCES (OTCMKTS:AVXLD), and Dominovas Energy (OTCMKTS

NRG).

Be On Top Of the Latest Developments - Research on Elite Pharmaceuticals, NanoTech Entertainment, Medbox and Bioelectronics
ACCESSWIRE - Wed Oct 28, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 28, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Elite Pharmaceuticals Inc. (OTC: ELTP), NanoTech Entertainment, Inc. (OTC: NTEK), Medbox Inc. (OTC: MDBX) and Bioelectronics Corp. (OTC: BIEL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.

Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
GlobeNewswire - Wed Oct 21, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of its lead opioid abuse-deterrent candidate, ELI-200, for the treatment of moderate to severe pain.

Elite Pharmaceuticals collects record revenues of USD7.1m for Q1 fiscal 2016
M2 - Tue Aug 11, 4:52AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Monday that it recorded consolidated revenues of USD7.1m for the quarter ended 30 June 2015, the first quarter of its 2016 fiscal year.

Elite Pharmaceuticals, Inc. Reports Record Revenues for First Quarter of Fiscal Year 2016
GlobeNewswire - Mon Aug 10, 3:20PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), announced results for the quarter ended June 30, 2015, the first quarter of its 2016 fiscal year.

Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
GlobeNewswire - Thu Aug 06, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its first quarter financial results will be released on Monday, August 10, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, August 11 at 11:00 a.m. Eastern Daylight Time to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
GlobeNewswire - Mon Aug 03, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCQB:ELTP), today announced the completion of patient enrollment and dosing for the Phase III efficacy trial for ELI-200, an abuse-deterrent opioid product. This Phase III trial is designed to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery. The study enrolled 163 patients at five clinical sites. Top-line efficacy and safety data from this study are expected to be announced near year's end. Submission of the NDA for ELI-200 is also expected shortly thereafter. "I am very pleased that we have completed enrollment, surgeries and dosing for Elite's Phase III trial for ELI-200," stated Nasrat Hakim, President and Chief Executive Officer of Elite. "We expect the NDA submission for ELI-200 near year's end, and in preparation for an ELI-200 launch in 2016, we are expanding our facility and working with our sales partner, Epic Pharma, on pre-launch activities."

Elite Pharmaceuticals awarded new US patent for abuse deterrent technology
M2 - Wed Jun 17, 4:25AM CDT
Pharmaceutical company Elite Pharmaceutical (OTCBB:ELTP) reported on Tuesday the receipt of the US Patent entitled "Abuse-Resistant Oral Dosage Forms" for its opioid abuse deterrent technology.

Elite Pharmaceutical's (ELTP) CEO Nasrat Hakim on Q4 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Jun 16, 7:50PM CDT

Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Jun 16, 9:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today the issuance of U.S. Patent No. 9,056,054 entitled "Abuse-Resistant Oral Dosage Forms". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NAPCO Security's Innovative Push at ISC East 2026

NAPCO's New Showcase at ISC East 2026 Let's dive into NAPCO Security Technologies' latest development, because these folks are taking the stage at the ISC East 2026, one of the big kahunas in security trade shows. Happening on November 4th and 5th at the Jacob Javits Center, the booth near the main entrance will be the place to catch the latest from this New York outfit,...

Valmet Fuels Century Sunshine's Pulp Revolution

Valmet's Bold Move in China's Pulp Industry Alright, let's dive deep into this pulp mill saga. Valmet isn't some novice in the industrial playing field, and their latest venture is a testament to that. They've clinched a hefty deal exceeding EUR 100 million to outfit Century Sunshine's Rizhao pulp mill in Shandong. This isn't just some small-time endeavor; it's a...

RISION Launches Torix: Affordable Thermal Imaging

A Thermal Leap Forward Ah, technology. Especially when it promises a new and shiny gadget that does more and costs less. Folks, RISION just threw another wrench in the works of the personal thermal imaging market. Their latest piece of kit, the RISION Torix, is now in the spotlight. Yep, we're talking about a handheld thermal camera that vows not to suck your wallet dry...

Trilogy Metals Advances Arctic Project's Potential

Trilogy Metals Completes Ambler Metals Field Work Alright, folks, let's dive into a mining story that should catch the discerning eye. Trilogy Metals (NYSE: TMQ) proudly wrapped up its 2026 field season at the Upper Kobuk Mineral Projects (UKMP), located in northwestern Alaska. And if you're neck-deep in the mining sector, this isn't just a thing on the periphery; it's a...

Primoris Faces Allegations Over Misleading Project Costs

Primoris in the Legal Crosshairs Here's something that's bound to rile up any investor keeping tabs on NYSE: PRIM like it's their personal stock ticker. Apparently, Primoris Services Corporation has found itself neck-deep in some murky waters. This time, it's law firm Moore Law PLLC that's raising the alarm bells, calling on shareholders to step into the legal ring....

Nasdaq Outruns Small Caps as Crude Falters

Here's a funny thing: A market that's galloping while its commodities counterpart stumbles. We're talking now about the Nasdaq and small caps flexing some serious muscle, pushing higher over a span of three sessions. These growth stocks took the lead, as the Nasdaq Composite inched up 1.04% for the day and gained 2.14% this week, ending at 26,700.62. The Russell 2000...

Michaels' Report: Holiday Season Trends in 2026

Making the Holidays Personal: A New Shift As holiday lights flicker on in neighborhoods across the country, what's lighting up more than just front yards this year is a shift in consumer desires. The 2026 Michaels State of the Holiday Season Report, crafted meticulously with Morning Consult, reveals some trends that just might shake up how folks celebrate this year....

Anita Eno: 2027's Top Trailblazing Businesswoman

Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...

Renue's Skincare Study: Promising Results on Aging Skin

A New Chapter in Skin Aging Research Here's a twist in the skincare narrative you probably weren't expecting—someone's finally paying attention to aging body skin. Cue the applause for Renue By Science, the folks who released a new white paper uncovering positive findings on their Renue Blue Moisturizing Body Cream. Ignoring the usual fixation on facial creams, this...

Home Remodeling: Stages, Setbacks, and Strategies

Home Remodeling: More Than Just a Facelift Ah, the prospect of turning your house into your dream home—sounds idyllic until you're knee-deep in dusty chaos. Remodeling isn't a walk in the park; it's a marathon filled with pitfalls and rollercoaster emotions. According to Brian Ward from Ward Construction & Remodeling, the process has set stages, and knowing these can...